Effects of α-tocopherol on an animal model of tauopathies

Free Radical Biology and Medicine

Volumn 37, Issue 2, 2004, Pages 176-186

  Nakashima, Hanae ^a   Ishihara, Takeshi ^a   Yokota, Osamu ^a   Terada, Seishi ^a   Trojanowski, John Q ^b   Lee, Virginia M Y ^b   Kuroda, Shigetoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Tocopherol; AD; Alzheimer's disease; Antioxidant; central nervous system; CNS; FA; formic acid; Free radicals; frontotemporal dementia with parkinsonism linked to chromosome 17; FTDP 17; MAb; Oxidative stress; Tauopathies; Transgenic mouse; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARGYROPHILIA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; GENE OVEREXPRESSION; MALE; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TAUOPATHY; VITAMIN SUPPLEMENTATION;

ALPHA-TOCOPHEROL; ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; BRAIN; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; FEMALE; HETEROZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; OXYGEN; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); PROTEIN ISOFORMS; SPINAL CORD; TAU PROTEINS; TAUOPATHIES; TIME FACTORS; TRANSGENES;

ANIMALIA; MUS MUSCULUS;

EID: 2942528891     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2004.04.037     Document Type: Article

References (88)

1. Lee V.M.-Y., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24:2001;1121-1159
2. Foster N.L., Wilhelmsen K., Sima A.A., Jones M.Z., D'Amato C.J., Gilman S. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Ann. Neurol. 41:1997;706-715
3. Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C., Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M., Joosse M., Kwon J.M., Nowotny P., Heutink P., et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 393:1998;702-705
4. Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L., Andreadis A., Wiederholt W.C., Raskind M., Schellenberg G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43:1998;815-825
5. Spillantini M.G., Murrell J.R., Goedert M., Farlow M.R., Klug A., Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA. 95:1998;7737-7741
6. Ishihara T., Higuchi M., Zhang B., Yoshiyama Y., Hong M., Trojanowski J.Q., Lee V.M.-Y. Attenuated neurodegenerative disease phenotype in tau transgenic mouse lacking neurofilaments. J. Neurosci. 21:2001;6026-6035
7. Ishihara T., Hong M., Zhang B., Nakagawa Y., Lee M.K., Trojanowski J.Q., Lee V.M.-Y. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron. 24:1999;751-762
8. Ishihara T., Zhang B., Higuchi M., Yoshiyama Y., Trojanowski J.Q., Lee V.M.-Y. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am. J. Pathol. 158:2001;555-562
9. Higuchi M., Ishihara T., Zhang B., Hong M., Andreadis A., Trojanowski J., Lee V.M.-Y. Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration. Neuron. 35:2002;433-446
10. Allen B., Ingram E., Takao M., Smith M.J., Jakes R., Virdee K., Yoshida H., Holzer M., Craxton M., Emson P.C., Atzori C., Migheli A., Crowther R.A., Ghetti B., Spillantini M.G., Goedert M. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22:2002;9340-9351
11. Duff K., Knight H., Refolo L.M., Sanders S., Yu X., Picciano M., Malester B., Hutton M., Adamson J., Goedert M., Burki K., Davies P. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol. Dis. 7:2000;87-98
12. Probst A., Gotz J., Wiederhold K.H., Tolnay M., Mistl C., Jaton A.L., Hong M., Ishihara T., Lee V.M.-Y., Trojanowski J.Q., Jakes R., Crowther R.A., Spillantini M.G., Burki K., Goedert M. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol. (Berlin). 99:2000;469-481
13. Spittaels K., Van den Haute C., Van Dorpe J., Bruynseels K., Vandezande K., Laenen I., Geerts H., Mercken M., Sciot R., Van Lommel A., Loos R., Van Leuven F. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am. J. Pathol. 155:1999;2153-2165
14. Brion J.P., Tremp G., Octave J.N. Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. Am. J. Pathol. 154:1999;255-270
15. Gotz J., Chen F., Barmettler R., Nitsch R.M. Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 276:2001;529-534
16. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25:2000;402-405
17. Tanemura K., Murayama M., Akagi T., Hashikawa T., Tominaga T., Ichikawa M., Yamaguchi H., Takashima A. Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J. Neurosci. 22:2002;133-141
18. Bramblett G.T., Trojanowski J.Q., Lee V.M.-Y. Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau-isoforms (A68 proteins). Lab. Invest. 66:1992;212-222
19. Lee V.M.-Y., Balin B.J., Otvos L. Jr., Trojanowski J.Q. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science. 251:1991;675-678
20. Matsuo E.S., Shin R.W., Billingsley M.L., Van deVoorde A., O'Connor M., Trojanowski J.Q., Lee V.M.-Y. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron. 13:1994;989-1002
21. Goedert M., Trojanowski J.Q., Lee V.M.-Y. The neurofibrillary pathology of Alzheimer's disease. Prusiner S.B., et al. The molecular and genetic basis of neurological diseases. 1997;613-627 Butterworth-Heinemann, Boston
22. Yamada K., Tanaka T., Han D., Senzaki K., Kameyama T., Nabeshima T. Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)- induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. Eur. J. Neurosci. 11:1999;83-90
23. Shea T.B., Rogers E., Ashline D., Ortiz D., Duarte N., Wilson T.O., Nicolosi R.J., Sheu M.S. Vitamin E deficiency does not induce compensatory antioxidant increases in central nervous system tissue of apolipoprotein E-deficient mice. J. Alzheimer's Dis. 5:2003;9-14
24. Melo J.B., Agostinho P., Oliveira C.R. Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide. Neurosci. Res. 45:2003;117-127
25. Guan Z.Z., Yu W.F., Shan K.R., Nordman T., Olsson J., Nordberg A. Loss of nicotinic receptors induced by beta-amyloid peptides in PC12 cells: possible mechanism involving lipid peroxidation. J. Neurosci. Res. 71:2003;397-406
26. Choi J., Conrad C.C., Dai R., Malakowsky C.A., Talent J.M., Carroll C.A., Weintraub S.T., Gracy R.W. Vitamin E prevents oxidation of antiapoptotic proteins in neuronal cells. Proteomics. 3:2003;73-77
27. Tabet N., Mantle D., Walker Z., Orrell M. Endogenous antioxidant activities in relation to concurrent vitamins A, C, and E intake in dementia. Int. Psychogeriatr. 14:2002;7-15
28. Stanyer L., Betteridge D.J., Smith C.C. An investigation into the mechanisms mediating plasma lipoprotein-potentiated beta-amyloid fibrillogenesis. FEBS Lett. 518:2002;72-78
29. Pratico D., Uryu K., Sung S., Tang S., Trojanowski J.Q., Lee V.M.-Y. Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB J. 16:2002;1138-1140
30. Munoz F.J., Opazo C., Gil-Gomez G., Tapia G., Fernandez V., Valverde M.A., Inestrosa N.C. Vitamin E but not 17beta-estradiol protects against vascular toxicity induced by beta-amyloid wild type and the Dutch amyloid variant. J. Neurosci. 22:2002;3081-3089
31. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Aggarwal N., Wilson R.S., Scherr P.A. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA. 287:2002;3230-3237
32. Engelhart M.J., Geerlings M.I., Ruitenberg A., van Swieten J.C., Hofman A., Witteman J.C., Breteler M.M. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA. 287:2002;3223-3229
33. Bonner L.T., Peskind E.R. Pharmacologic treatments of dementia. Med. Clin. North Am. 86:2002;657-674
34. Jang J.H., Surh Y.J. Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic. Biol. Med. 34:2003;1100-1110
35. Koppaka V., Paul C., Murray I.V., Axelsen P.H. Early synergy between Abeta 42 and oxidatively damaged membranes in promoting amyloid fibril formation by Abeta 40. J. Biol. Chem. 2003
36. Marques C.A., Keil U., Bonert A., Steiner B., Haass C., Muller W.E., Eckert A. Neurotoxic mechanisms caused by the Alzheimer's disease-linked Swedish amyloid precursor protein mutation: oxidative stress, caspases, and the JNK pathway. J. Biol. Chem. 278:2003;28294-28302
37. Strazielle C., Sturchler-Pierrat C., Staufenbiel M., Lalonde R. Regional brain cytochrome oxidase activity in beta-amyloid precursor protein transgenic mice with the Swedish mutation. Neuroscience. 118:2003;1151-1163
38. Tamagno E., Parola M., Guglielmotto M., Santoro G., Bardini P., Marra L., Tabaton M., Danni O. Multiple signaling events in amyloid beta-induced, oxidative stress-dependent neuronal apoptosis. Free Radic. Biol. Med. 35:2003;45-58
39. Varadarajan S., Yatin S., Aksenova M., Butterfield D.A. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130:2000;184-208
40. Andrekopoulos C., Zhang H., Joseph J., Kalivendi S., Kalyanaraman B. Bicarbonate enhances alpha-synuclein oligomerization and nitration: intermediacy of carbonate radical anion and nitrogen dioxide radical. Biochem. J. 378:2004;435-447
41. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 302:2003;819-822
42. Ischiropoulos H. Oxidative modifications of alpha-synuclein. Ann. N. Y. Acad. Sci. 991:2003;93-100
43. Ischiropoulos H., Beckman J.S. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J. Clin. Invest. 111:2003;163-169
44. +-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J. Biol. Chem. 2004
45. Kong B., Chae Y.K., Lee K. Regulation of in vitro fibril formation of synuclein mutant proteins by Hsp104p. Protein Pept. Lett. 10:2003;491-495
46. Norris E.H., Giasson B.I., Ischiropoulos H., Lee V.M.-Y. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J. Biol. Chem. 278:2003;27230-27240
47. Wersinger C., Prou D., Vernier P., Sidhu A. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J. 17:2003;2151-2153
48. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M.-Y. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 290:2000;985-989
49. Lee V.M.-Y., Wang J., Trojanowski J.Q. Purification of paired helical filament tau and normal tau from human brain tissue. Methods Enzymol. 309:1999;81-89
50. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21:2001;8370-8377
51. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell. 101:2000;57-66
52. Machlin L.J., Gabriel E. Kinetics of tissue alpha-tocopherol uptake and depletion following administration of high levels of vitamin E. Ann. N. Y. Acad. Sci. 393:1982;48-60
53. Ihara Y., Hayabara T., Sasaki K., Fujisawa Y., Kawada R., Yamamoto T., Nakashima Y., Yoshimune S., Kawai M., Kibata M., Kuroda S. Free radicals and superoxide dismutase in blood of patients with Alzheimer's disease and vascular dementia. J. Neurol. Sci. 153:1997;76-81
54. Sinclair A.J., Bayer A.J., Johnston J., Warner C., Maxwell S.R. Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int. J. Geriatr. Psychiatry. 13:1998;840-845
55. Conrad C.C., Marshall P.L., Talent J.M., Malakowsky C.A., Choi J., Gracy R.W. Oxidized proteins in Alzheimer's plasma. Biochem. Biophys. Res. Commun. 275:2000;678-681
56. Pratico D., Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am. J. Med. 109:2000;577-585
57. Serra J.A., Dominguez R.O., de Lustig E.S., Guareschi E.M., Famulari A.L., Bartolome E.L., Marschoff E.R. Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients. J. Neural Transm. 108:2001;1135-1148
58. Ryglewicz D., Rodo M., Kunicki P.K., Bednarska-Makaruk M., Graban A., Lojkowska W., Wehr H. Plasma antioxidant activity and vascular dementia. J. Neurol. Sci. 203-204:2002;195-197
59. Andrus P.K., Fleck T.J., Gurney M.E., Hall E.D. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 71:1998;2041-2048
60. Aguirre T., Van Den Bosch L., Goetschalckx K., Tilkin P., Mathijs G., Cassiman J.J., Robberecht W. Increased sensitivity of fibroblasts from amyotrophic lateral sclerosis patients to oxidative stress. Ann. Neurol. 43:1998;452-457
61. Tu P.H., Gurney M.E., Julien J.P., Lee V.M.-Y., Trojanowski J.Q. Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. Lab. Invest. 76:1997;441-456
62. Browne S.E., Ferrante R.J., Beal M.F. Oxidative stress in Huntington's disease. Brain Pathol. 9:1999;147-163
63. Klivenyi P., Ferrante R.J., Gardian G., Browne S., Chabrier P.E., Beal M.F. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J. Neurochem. 86:2003;267-272
64. Segovia J. Transgenic model for the study of oxidative damage in Huntington's disease. Methods Enzymol. 353:2002;365-373
65. Snider B.J., Moss J.L., Revilla F.J., Lee C.S., Wheeler V.C., Macdonald M.E., Choi D.W. Neocortical neurons cultured from mice with expanded CAG repeats in the huntingtin gene: unaltered vulnerability to excitotoxins and other insults. Neuroscience. 120:2003;617-625
66. Harvey B.H., Nel A. Role of aging and striatal nitric oxide synthase activity in an animal model of tardive dyskinesia. Brain Res. Bull. 61:2003;407-416
67. Lohr J.B., Kuczenski R., Niculescu A.B. Oxidative mechanisms and tardive dyskinesia. CNS Drugs. 17:2003;47-62
68. Michael N., Sourgens H., Arolt V., Erfurth A. Severe tardive dyskinesia in affective disorders: treatment with vitamin E and C. Neuropsychobiology. 46(Suppl. 1):2002;28-30
69. Sachdev P., Saharov T., Cathcart S. The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia. Biol. Psychiatry. 46:1999;1672-1681
70. Calabrese V., Bella R., Testa D., Spadaro F., Scrofani A., Rizza V., Pennisi G. Increased cerebrospinal fluid and plasma levels of ultraweak chemiluminescence are associated with changes in the thiol pool and lipid-soluble fluorescence in multiple sclerosis: the pathogenic role of oxidative stress. Drugs Exp. Clin. Res. 24:1998;125-131
71. Mehindate K., Sahlas D.J., Frankel D., Mawal Y., Liberman A., Corcos J., Dion S., Schipper H.M. Proinflammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis. J. Neurochem. 77:2001;1386-1395
72. Joseph J.A., Denisova N.A., Bielinski D., Fisher D.R., Shukitt-Hale B. Oxidative stress protection and vulnerability in aging: putative nutritional implications for intervention. Mech. Ageing Dev. 116:2000;141-153
73. Egana J.T., Zambrano C., Nunez M.T., Gonzalez-Billault C., Maccioni R.B. Iron-induced oxidative stress modifies tau phosphorylation patterns in hippocampal cell cultures. Biometals. 16:2003;215-223
74. Gomez-Ramos A., Diaz-Nido J., Smith M.A., Perry G., Avila J. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J. Neurosci. Res. 71:2003;863-870
75. Kim D., Koh W.K., Kim J.U., Lee J.H., Hong H.N. Okadaic acid-induced upregulation of nitrotyrosine and heme oxygenase-1 in rat cortical neuron cultures. Neurosci. Lett. 297:2001;33-36
76. Stamer K., Vogel R., Thies E., Mandelkow E., Mandelkow E.M. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 156:2002;1051-1063
77. Zhu X., Rottkamp C.A., Boux H., Takeda A., Perry G., Smith M.A. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J. Neuropathol. Exp. Neurol. 59:2000;880-888
78. Takeda A., Perry G., Abraham N.G., Dwyer B.E., Kutty R.K., Laitinen J.T., Petersen R.B., Smith M.A. Overexpression of heme oxygenase in neuronal cells, the possible interaction with Tau. J. Biol. Chem. 275:2000;5395-5399
79. Perez M., Hernandez F., Gomez-Ramos A., Smith M., Perry G., Avila J. Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. Eur. J. Biochem. 269:2002;1484-1489
80. D'Souza I., Poorkaj P., Hong M., Nochlin D., Lee V.M.-Y., Bird T.D., Schellenberg G.D. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc. Natl. Acad. Sci. USA. 96:1999;5598-5603
81. Hong M., Zhukareva V., Vogelsberg-Ragaglia V., Wszolek Z., Reed L., Miller B.I., Geschwind D.H., Bird T.D., McKeel D., Goate A., Morris J.C., Wilhelmsen K.C., Schellenberg G.D., Trojanowski J.Q., Lee V.M.-Y. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science. 282:1998;1914-1917
82. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60:2001;759-767
83. Nunomura A., Perry G., Pappolla M.A., Wade R., Hirai K., Chiba S., Smith M.A. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 19:1999;1959-1964
84. Deschamps V., Barberger-Gateau P., Peuchant E., Orgogozo J.M. Nutritional factors in cerebral aging and dementia: epidemiological arguments for a role of oxidative stress. Neuroepidemiology. 20:2001;7-15
85. Butterfield D., Castegna A., Pocernich C., Drake J., Scapagnini G., Calabrese V. Nutritional approaches to combat oxidative stress in Alzheimer's disease. J. Nutr. Biochem. 13:2002;444
86. Otsuka M., Yamaguchi K., Ueki A. Similarities and differences between Alzheimer's disease and vascular dementia from the viewpoint of nutrition. Ann. N. Y. Acad. Sci. 977:2002;155-161
87. Reynish W., Andrieu S., Nourhashemi F., Vellas B. Nutritional factors and Alzheimer's disease. J. Gerontol. A Biol. Sci. Med. Sci. 56:2001;M675-M680
88. Foley D.J., White L.R. Dietary intake of antioxidants and risk of Alzheimer disease: food for thought. JAMA. 287:2002;3261-3263